<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03084861</url>
  </required_header>
  <id_info>
    <org_study_id>I.2016.010</org_study_id>
    <nct_id>NCT03084861</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy</brief_title>
  <official_title>A Multicenter, Randomized, Open-label, Two-arms Phase I/II Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banc de Sang i Teixits</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Banc de Sang i Teixits</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open-label, two-arms phase I/II, clinical trial, in which
      42 patients will be enrolled with the principal objective to evaluate the efficacy through
      changes in lesion size and, secondary, to evaluate the safety and efficacy through corneal
      sensibility, corneal opacity, visual acuity and complications of Neurotrophic Keratopathy
      (NK). Patients will be randomized 1:1 to receive experimental treatment (cord blood eye
      drops) or conventional treatment (artificial tears and therapeutic contact lens).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, open-label, two-arms phase I/II, clinical trial, in which
      42 patients will be enrolled with the principal objective to evaluate the efficacy through
      changes in lesion size and, secondary, to evaluate the safety and efficacy through corneal
      sensibility, corneal opacity, visual acuity and complications of NK. Patients will be
      randomized 1:1 to receive experimental treatment (cord blood eye drops) or conventional
      treatment (artificial tears and therapeutic contact lens).

      All patients, with conventional or experimental treatment, will be treated for 19 days. A
      topical antibiotic will be added too as a concomitant treatment to all treatment groups,
      until the injury closes or according to medical criteria.

      After signing informed consent, inclusion and exclusion criteria will be assessed, and if the
      patient meets all the requirements, the patient will be randomized.

      After initiation of the treatment, patients will be follow-up at 2-3 days and once a week for
      3 weeks. A final follow-up is planned at 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2017</start_date>
  <completion_date type="Anticipated">April 7, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 17, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal lesion size</measure>
    <time_frame>after 3 weeks post-treatment,</time_frame>
    <description>Variation percentage in corneal lesion size</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>From date of randomization until the date of the last visit (6 weeks post-treatment)</time_frame>
    <description>Safety evaluation through laboratory data and adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal lesion size</measure>
    <time_frame>at 2-3 days post-treatment and at 1, 2 and 6 weeks post-treatment</time_frame>
    <description>Variation percentage in corneal lesion size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage on the corneal lesion</measure>
    <time_frame>at 3 weeks post-treatment</time_frame>
    <description>Changes stage on the corneal lesion (cured, stage 1, stage 2, stage 3) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative scale of corneal sensibility</measure>
    <time_frame>at 2-3 days post-treatment and at 1, 2, 3 and 6 weeks post-treatment</time_frame>
    <description>Changes in qualitative scale of corneal sensibility (normoesthesia, hypoesthesia, anesthesia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal opacity</measure>
    <time_frame>at 2-3 days post-treatment and at 1, 2, 3 and 6 weeks post-treatment</time_frame>
    <description>Changes on corneal opacity from baseline (not response, improvement, worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>at 2-3 days post-treatment and at 1, 2 and 6 weeks post-treatment</time_frame>
    <description>Line variation in relation to visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurotrophic keratopathy</measure>
    <time_frame>From date of randomization until the date of the last visit (6 weeks post-treatment)</time_frame>
    <description>Number of neurotrophic keratopathy complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Neurotrophic Keratopathy</condition>
  <arm_group>
    <arm_group_label>cord blood eye drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental drug: cord blood eye drops Description: eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 19 vials of 1 mL per vial Route of administration: ophthalmic/ocular</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional treatment:
Artificial tears Description: Lubristil ® (single dose) Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 20 or 30 vials of 0.3 mL per vial Route of administration: ophthalmic
Therapeutic Contact lens Description: Air Optix Night&amp;Day Dosage regimen: 1 contact lens per visit Pharmaceutical form: contact lens Presentation: 1 unit per case Route of administration: ophthalmic/ocular</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cord Blood Eye Drops</intervention_name>
    <description>Eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives</description>
    <arm_group_label>cord blood eye drops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional treatment</intervention_name>
    <description>Artificial tears: Lubristil ®
Therapeutic Contact lens: Air Optix Night&amp;Day</description>
    <arm_group_label>Conventional treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years old

          2. NK stage 2 or 3 (Mackie classification)

          3. Signed Informed Consent Form

          4. The patient is able to understand the nature of the study and to participate
             throughout its duration

        Exclusion Criteria:

          1. Medical history of eye tumors

          2. Active eye infection

          3. Eyelid bad position or eyelid closure problems

          4. Conjunctiva scarring

          5. Topic chronic eye treatments with corticoids

          6. Acute corneal burns (&lt;3 months)

          7. Intolerance to contact lens

          8. Allergy or inability to receive concomitant treatment with Exocin®

          9. Patients with immunosuppressive or chemotherapy treatment

         10. Pregnant woman or woman without proper contraceptive methods according to the
             investigator (*), or lactating women

         11. Participation in another clinical trial in the last month (*) Contraceptive methods
             accepted in the protocol are: hormonal, intrauterine device (IUD), barrier methods,
             voluntary sterilization or the patient has menopause &gt;1 year duration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergi Querol Giner, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Banc de Sang i Teixits</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dinara Samarkanova, MD</last_name>
    <phone>+34935573500</phone>
    <phone_ext>6563</phone_ext>
    <email>dsamarkanova@bst.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruth Coll Bonet, MD</last_name>
    <phone>+34935573500</phone>
    <phone_ext>6707</phone_ext>
    <email>rucoll@bst.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoraida Del Campo Carrasco, MD</last_name>
      <phone>+34935565775</phone>
      <email>ZCampo@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Zoraida Del Campo Carrasco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Puig Galy, MD PHD</last_name>
      <phone>+34932746000</phone>
      <email>lospuig.javier@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2017</study_first_submitted>
  <study_first_submitted_qc>March 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2017</study_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

